Journal of Vascular and Interventional Radiology最新文献

英文中文

Cryoablation Protocols for Primary and Metastatic Lung Tumors: A Systematic Review and Meta-Analysis Evaluating Effectiveness and Safety of Percutaneous Cryoablation of Pulmonary Tumors 原发性和转移性肺肿瘤的冷冻消融方案：一项评估经皮肺肿瘤冷冻消融有效性和安全性的系统综述和荟萃分析。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.004

Arman Sarshoghi , Arash Sarshoghi MSc , Maxime Têtu MSc , Calvin S.H. Ng MD , Lonny Yarmus DO , Patrick Bourgouin MD , Stephen B. Solomon MD , Felix Herth MD, PhD , Robert P. Liddell MD , Moishe Liberman MD, PhD

Purpose

To evaluate 1-year local tumor control (LTC) after percutaneous cryoablation for lung tumors and to identify procedural protocol and patient/tumor characteristics associated with improved outcomes.

Materials and Methods

A systematic search of PubMed, Embase, and Web of Science was conducted. The primary outcome was LTC at 1 year. Secondary outcomes included the identification of factors associated with LTC and pooled adverse event rates, such as freezing lengths, number of cycles, tumor characteristics, and more. Data were pooled using a random-effects model, and meta-regression was used to analyze factors affecting LTC.

Results

Nineteen studies (786 patients, 1,048 tumors) yielded a pooled 1-year LTC of 90.5% (95% CI, 85.1%–94.1%). Multivariate meta-regression showed that smaller tumor size was significantly associated with improved LTC. Univariate analysis also identified that superior LTC was associated with a triple freeze-thaw protocols (vs double), a shorter first freeze duration, a longer final freeze duration, and ending the procedure with a thaw cycle. The incidence of adverse events (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥3) was 4.9% (95% CI, 2.9%–6.9%), with pneumothorax most common (28% of cases).

Conclusions

Percutaneous cryoablation demonstrates high effectiveness for lung tumor control. Superior 1-year LTC is associated with smaller tumor size and a triple freeze-thaw protocol characterized by a short initial freeze followed by longer subsequent freezes. These findings provide a data-driven basis for standardizing cryoablation techniques.

目的：本系统综述和荟萃分析旨在评估经皮肺肿瘤冷冻消融后1年的局部肿瘤控制（LTC），并确定与改善预后相关的手术方案和患者/肿瘤特征。方法：系统检索PubMed、EMBASE和Web of Science。主要终点为1年LTC。次要结局包括确定与LTC和汇总不良事件发生率相关的因素，如冷冻时间、周期数、肿瘤特征等。采用随机效应模型对数据进行汇总，并采用元回归分析影响LTC的因素。结果：19项研究（786例患者，1048个肿瘤）得出的1年总LTC为90.5% （95% CI, 85.1%-94.1%）。多变量荟萃回归显示，较小的肿瘤大小与LTC改善显著相关。单变量分析还发现，较好的LTC与三次冻融方案（与两次冻融方案相比）、较短的首次冻融持续时间、较长的最终冻融持续时间以及以解冻周期结束的过程有关。不良事件（CTCAE分级≥3）发生率为4.9% (95% CI: 2.9%-6.9%)，其中气胸最为常见（28%的病例）。结论：经皮冷冻消融治疗肺肿瘤疗效显著。优越的1年LTC与较小的肿瘤大小和三重冻融方案相关，其特征是初始冻结时间短，随后冻结时间长。这些发现为标准化冷冻消融技术提供了数据驱动的基础。

{"title":"Cryoablation Protocols for Primary and Metastatic Lung Tumors: A Systematic Review and Meta-Analysis Evaluating Effectiveness and Safety of Percutaneous Cryoablation of Pulmonary Tumors","authors":"Arman Sarshoghi , Arash Sarshoghi MSc , Maxime Têtu MSc , Calvin S.H. Ng MD , Lonny Yarmus DO , Patrick Bourgouin MD , Stephen B. Solomon MD , Felix Herth MD, PhD , Robert P. Liddell MD , Moishe Liberman MD, PhD","doi":"10.1016/j.jvir.2025.10.004","DOIUrl":"10.1016/j.jvir.2025.10.004","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate 1-year local tumor control (LTC) after percutaneous cryoablation for lung tumors and to identify procedural protocol and patient/tumor characteristics associated with improved outcomes.</div></div><div><h3>Materials and Methods</h3><div>A systematic search of PubMed, Embase, and Web of Science was conducted. The primary outcome was LTC at 1 year. Secondary outcomes included the identification of factors associated with LTC and pooled adverse event rates, such as freezing lengths, number of cycles, tumor characteristics, and more. Data were pooled using a random-effects model, and meta-regression was used to analyze factors affecting LTC.</div></div><div><h3>Results</h3><div>Nineteen studies (786 patients, 1,048 tumors) yielded a pooled 1-year LTC of 90.5% (95% CI, 85.1%–94.1%). Multivariate meta-regression showed that smaller tumor size was significantly associated with improved LTC. Univariate analysis also identified that superior LTC was associated with a triple freeze-thaw protocols (vs double), a shorter first freeze duration, a longer final freeze duration, and ending the procedure with a thaw cycle. The incidence of adverse events (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥3) was 4.9% (95% CI, 2.9%–6.9%), with pneumothorax most common (28% of cases).</div></div><div><h3>Conclusions</h3><div>Percutaneous cryoablation demonstrates high effectiveness for lung tumor control. Superior 1-year LTC is associated with smaller tumor size and a triple freeze-thaw protocol characterized by a short initial freeze followed by longer subsequent freezes. These findings provide a data-driven basis for standardizing cryoablation techniques.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107871"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Session Ethanol Sclerotherapy for Symptomatic Simple Adrenal Cysts 单期乙醇硬化疗法治疗单纯性肾上腺囊肿。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.008

Peter M. Do BS , James Y. Lim MD , Keith B. Quencer MD , Brian J. Park MD, MS

引用次数: 0

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01

引用次数: 0

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01

引用次数: 0

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01

引用次数: 0

Cover 封面

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/S1051-0443(25)00787-0

引用次数: 0

Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases 肿瘤吸收剂量、代谢反应和乳腺癌肝转移患者放射栓塞后的生存。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.045

Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD

Purpose

To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (⁹⁰Y) transarterial radioembolization (TARE).

Materials and Methods

Between August 2016 and August 2024, patients with BCLM who underwent ⁹⁰Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.

Results

Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).

Conclusions

Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.

目的：探讨经动脉放射栓塞（TARE）治疗乳腺癌肝转移（BCLM）患者肿瘤吸收剂量（TAD）与肿瘤反应及生存期的关系。方法与材料：回顾性分析2016年8月至2024年8月间行玻璃颗粒Y90-TARE治疗的BCLM患者。主要结局是总生存期（OS）和肝脏无进展生存期（hPFS）。次要终点为客观有效率。使用实体瘤正电子发射断层扫描反应标准（PERCIST）评估对治疗的反应。患者分为有反应组和无反应组。结果或发现：42例女性中有26例患者符合纳入标准，平均年龄为57.9±13.8岁。所有患者的中位OS和hPFS分别为6.1个月（IQR; 4.3-9.0个月）和4.2个月（IQR; 2.5-5.6个月）。应答者和无应答者的中位TAD分别为157 Gy和150 Gy （p=0.768）。应答者与无应答者的中位OS和hPFS分别为8.3个月（IQR; 5.5-14.8个月）和4.1个月（IQR; 3.1-6.3个月），而4.0个月（IQR; 2.5-4.5个月）和2.1个月（IQR; 1.3-2.7个月），分别为（p= 0.025和p= 0.210）。在145 Gy以上，TAD表现出显著的OS获益，但没有改变肝脏hPFS （p = 0.024和p = 0.397）。结论：在本研究中，影像学反应与OS有一定相关性，而TAD与反应无相关性。

{"title":"Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases","authors":"Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD","doi":"10.1016/j.jvir.2025.08.045","DOIUrl":"10.1016/j.jvir.2025.08.045","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (<sup>90</sup>Y) transarterial radioembolization (TARE).</div></div><div><h3>Materials and Methods</h3><div>Between August 2016 and August 2024, patients with BCLM who underwent <sup>90</sup>Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.</div></div><div><h3>Results</h3><div>Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (<em>P</em> = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (<em>P</em> = .025 and <em>P</em> = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (<em>P</em> = .024 and <em>P</em> = .397, respectively).</div></div><div><h3>Conclusions</h3><div>Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107833"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01

引用次数: 0

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01

引用次数: 0

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Vascular and Interventional Radiology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀